Commitments & Contingencies (Details) - USD ($) $ in Thousands, shares in Millions |
1 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Jul. 31, 2021 |
Jul. 31, 2009 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Commitments And Contingencies [Line Items] | ||||
| Lease, Cost | $ 90 | |||
| Settlement agreement description | In July 2021, Legacy Clarus and Lipocine entered into a settlement agreement that settled all claims between the parties, including a pending interference matter (No. 106,128) and the pending Legacy Clarus counterclaims against Lipocine, and provided for a payment by Lipocine to Legacy Clarus of a $4.0 million settlement fee payable as follows: $2.5 million upfront, $1.0 million within 12 months, and the remainder within two years. The Company is recognizing the payments in income as they are received. The Company received payment of $2.5 million of the $4.0 million in July 2021, which is recorded within the litigation settlement line in other income and expense on the statement of operations. | |||
| Catalent Pharma Solutions L L C [Member] | ||||
| Commitments And Contingencies [Line Items] | ||||
| Annual Purchases | 7.0 | |||
| Lease Agreements [Member] | ||||
| Commitments And Contingencies [Line Items] | ||||
| Rent Expense | 200 | $ 200 | ||
| Catalent Agreement [Member] | ||||
| Commitments And Contingencies [Line Items] | ||||
| Purchase Amount | $ 6,200 | $ 3,200 | ||
| Pfizer Agreement [Member] | ||||
| Commitments And Contingencies [Line Items] | ||||
| Annual Purchases | 1.8 | |||
| Purchase Amount | $ 1,800 | |||